|27.90|| +0.35 / +1.27%|
Coherus BioSciences, Inc. engages in the development and commercializition of biosimilar therapeutics worldwide. Its clinical-stage pipeline consists of two anti-inflammatory agents targeting tumor necrosis factor, a substance in the body that is involved in the inflammatory response; and a long-acting form of granulocyte colony-stimulating factor, a beneficial substance in the body that stimulates production of granulocytes (a type of white blood cell) in order to promote the body's ability to fight infections. The company was founded by Dennis M. Lanfear and Stuart E. Builder in September 2010 and is headquartered in Redwood City, CA.
|Denny M. Lanfear||Chairman, President & Chief Executive Officer|
|Jean-Frédéric Viret||Chief Financial Officer|
|Alan C. Herman||Chief Scientific Officer|
|Peter K. Watler||Chief Technical Officer|
|Barbara K. Finck||Chief Medical Officer|